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Background: Hereditary haemorrhagic telangiectasia (HHT) is inherited as an autosomal dominant trait, affects ~1
in 5,000, and causes multi-systemic vascular lesions and life-limiting complications. Life expectancy is surprisingly
good, particularly for patients over 60ys. We hypothesised that individuals with HHT may be protected against
life-limiting cancers.
Methods: To compare specific cancer rates in HHT patients and controls, we developed a questionnaire capturing
data on multiple relatives per respondent, powered to detect differences in the four most common solid non skin
cancers (breast, colorectal, lung and prostate), each associated with significant mortality. Blinded to cancer
responses, reports of HHT-specific features allowed assignment of participants and relatives as HHT-subjects,
unknowns, or controls. Logistic and quadratic regressions were used to compare rates of specific cancer types
between HHT subjects and controls.
Results: 1,307 participants completed the questionnaire including 1,007 HHT-subjects and 142 controls. The rigorous
HHT diagnostic algorithm meant that 158 (12%) completed datasets were not assignable either to HHT or control
status. For cancers predominantly recognised as primary cancers, the rates in the controls generally matched
age-standardised rates for the general population. HHT subjects recruited through the survey had similar demographics
to controls, although the HHT group reported a significantly greater smoking habit. Combining data of participants and
uniquely-reported relatives resulted in an HHT-arm of 2,161 (58% female), and control-arm of 2,817 (52% female), with
median ages of 66ys [IQR 53–77] and 77ys [IQR 65–82] respectively. In both crude and age-adjusted regression, lung
cancers were significantly less frequent in the HHT arm than controls (age-adjusted odds ratio 0.48 [0.30, 0.70],
p = 0.0012). Breast cancer prevalence was higher in HHT than controls (age-adjusted OR 1.52 [1.07, 2.14], p = 0.018).
Overall, prostate and colorectal cancer rates were equivalent, but the pattern of colorectal cancer was modified, with a
higher prevalence in younger HHT patients than controls.
Conclusions: These preliminary survey data suggest clinically significant differences in the rates of lung, breast and
colorectal cancer in HHT patients compared to controls. For rare diseases in which longitudinal studies take decades to
recruit equivalent datasets, this type of methodology provides a good first-step method for data collection.
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Hereditary haemorrhagic telangiectasia (HHT, also known
as Osler-Weber-Rendu syndrome) is inherited as an auto-
somal dominant trait, and affects approximately 1 in 5,000
people [1,2,3]. Affected individuals have multi-systemic
vascular lesions that cause major morbidity and mortality
[4-6]. Telangiectasia in the nasal mucosa and gastro-
intestinal tract frequently haemorrhage leading to chronic
iron deficiency anaemia and often transfusion-dependence
[1,3,7,8]. Increasing age is associated with increasing severity
and prevalence of telangiectasia [3,6], gastrointestinal bleed-
ing [3,8], and comorbidities. Pulmonary, cerebral, spinal and
hepatic arteriovenous malformations (AVMs) affect high
proportions of patients with HHT, and commonly cause
complications including haemorrhagic [9], ischaemic [10]
and infective strokes; [10-12] other major haemorrhage; [13]
and maternal death in pregnancy [14]. Hepatic AVMs may
result in high output cardiac failure, and intractable compli-
cated portal hypertension requiring liver transplantation
[15,16]. Additional HHT-related pathologies include pul-
monary arterial hypertension (PAH) when the prognosis ap-
pears worse than for patients with PAH due to BMPR2
mutations [17], a higher risk of venous thromboemboli
(enhanced in the setting of iron deficiency) [18,19], and for
patients with SMAD4 mutations, colon cancer and other
gastrointestinal cancers related to their juvenile polyposis
[20,21]. Life-long monitoring and treatment is often needed.
Additionally, many patients report not taking secondary
prophylaxis such as anti-platelets and anti-coagulants in
view of the perceived risk of precipitating haemorrhage [22].
It would be reasonably expected that patients with such
severe potential disease complications, apparently increas-
ing with age, should have higher mortality rates than the
general population. Life expectancy data demonstrate a
higher mortality rate in HHT patients under 60 years of
age, consistent with early mortality due to AVMs, especially
cerebral AVM bleeds in childhood and young adults, and
pregnancy-related deaths [1,23]. In one study, a retrospec-
tive analysis of Italian HHT patients’ parents, increased
mortality was demonstrated across all age groups [23].
However, in a 30 year prospective study in Denmark there
was no evidence for an increase in mortality in HHT pa-
tients older than 60 years of age [1]. Although awaiting peer
review, more recent data on North American and European
cohorts, each of approximately 600 HHT patients or par-
ents, also suggest surprisingly good survival rates [24,25].
Amongst the explanations for the surprising life ex-
pectancy data could be that HHT-related mortality is
offset by a reduction in deaths from more common dis-
eases. Different rates of heart disease were proposed
some years ago, though never formally published [26], and
are the subject of a separate manuscript in preparation.
Based on personal and family histories from patients
attending our specialised HHT service, we hypothesisedthat HHT patients may have less frequent life-limiting
cancers.
Testing such a hypothesis in a rare disease population is
not simple. To provide preliminary data in a human popu-
lation even for the most common cancers such as breast,
colorectal, lung and prostate cancer, carries major statistical
and logistic difficulties. First, incidence rates (30–50 per
100,000 per annum for lung and colorectal cancers) are
prohibitively small for realistic prospective studies in a rare
disease population such as HHT. To generate sufficiently
sized cohorts for any form of analysis requires pooling of
cohorts from different geographical regions. This intro-
duces variance through combining data from genetically
unrelated populations, with differing risk factor exposures,
and spanning time periods with varying incidence rates
[27,28]. As a result, to have sufficient power to detect re-
ductions in cancer rates requires population sizes of many
thousands. Additionally, prior fatalities from life-limiting
cancers mean that affected individuals may not survive to
provide retrospective data at the point of clinic review or
questionnaire: in the UK, 5 year survival following breast
and prostate cancer is over 80%, but for colorectal cancer,
just over 50%, and for lung cancer, less than 10% [28]. Ani-
mal models are therefore favoured, but while instructive in
specific settings, such models cannot provide an integrated
picture of the lifetime exposure risks for people in the set-
ting of the repertoire of human genomic variation.
To design a study to test our hypothesis that cancer inci-
dence may be reduced in HHT, and provide data to allow
realistic power calculations to be performed for future
studies, we developed an online questionnaire. This ex-
tended the techniques we used to capture fatal HHT cere-
bral haemorrhages [29], and maternal deaths in pregnancy
[14], by allowing each individual to provide data on mul-
tiple family relatives. This method presents a means of
determining cancer rates at lower respondent/proband
numbers than if only a single case per respondent was cap-
tured; inclusion of relevant questions regarding other fam-
ily members allows identification of relatives that could
have been reported on multiple occasions so allowing each
to be captured only once. Questionnaire data are inevitably
weakened by the self reported nature, but comparison of
subject and control groups ascertained in comparable
manners provides an opportunity to compare rates, even if
these may not be formally assigned to classical incidence
or prevalence rates that demand pre-defined populations.
Here we report a questionnaire-based study, which
provides interesting suggestions that specific cancer types
may differ between people affected with HHTand controls.
Methods
Study design
To capture cancer-histories in an unbiased manner, rele-
vant questions were incorporated into a wider ethically-
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dicated that to distinguish incidence rates of the four
most common cancer subtypes would require unrealistic
response rates, so the study was designed to capture data
on multiple relatives per respondent. The basic study
design has been reported previously [22,30]. Briefly, in
order to prevent participants altering their answers to
conform to their guess of what the research hypothesis
was, (hypothesis guessing), multiple questionnaires were
incorporated into a single survey of questions regarding
health and treatments for people with HHT and general
population controls. As described elsewhere [22,30], the
questionnaire was approved by the NRES Committee
East Midlands-Derby 1 Research Ethics Committee, and
distributed by post, using the Imperial College London
HHTIC London Clinical Service databases (2001 to
present), during attendance at the HHT clinics, and adver-
tised by the HHT Foundation International [22,30,31].
Study design allowed participants the option of paus-
ing whilst completing the questionnaire and continuing
at a later time point, to optimise data collection and sur-
vey completion rates. Generic questions included in the
analyses for this study were age, gender, and HHT-related
questions which would permit independent assignment of
the respondent’s HHT-status based on the Curaçao cri-
teria [32], and allowed HHT-affected respondents to re-
port which parent and grandparent had HHT. Additional
questions addressed personal cancer history, family cancer
history, and prevalence of carcinogenic risk factors includ-
ing smoking habits, diet, and industrial exposure to che-
micals. These questions were not asked for the relatives
due to the excessive number of questions this would have
entailed, and the likelihood that no data would have been
gathered as participants would have decided to stop the
questionnaire. Specific relatives’ questions were therefore
limited to age, gender, relationship, if HHT was known to
be present, types of cancer present, age at first cancer, and
if HHT affected management (if relevant) of cancer treat-
ment (see Additional file 1 for exact wording). Free text
options were provided allowing additional details to be
reported.
Questions specifying particular cancers targeted the 20
most prevalent cancers in the western world [27,28] with
drop down boxes for 5 or 10 year age periods, and each
of the specified cancers: skin (basal, squamous, melanoma,
other, unsure), and non skin cancers (brain, bladder, breast,
cervical, colorectal, kidney, leukemia, liver, lung, lymph-
oma, malignant melanoma, mesothelioma, mouth, mye-
loma, oesophagus, ovary, pancreas, prostate, stomach and
uterus: see Additional file 1). All questions were standar-
dised, although room was left for personal comment. Study
methodology implied that it was not possible to ascertain
whether primary or secondary cancers were being re-
ported, but the methodology was identical for control andHHT groupings. In view of reported uncertainty regarding
the types of skin cancer present [27,28], it was not the
intention to analyse skin cancer data specifically: questions
were included however, to ensure these cancers were cap-
tured by survey questions before non skin cancers were
reported.
Power calculations
In view of the varied pathogenic mechanisms involved in
cancer subgroups, the primary study outcome was spe-
cific cancer types, namely the four most common non
skin cancers in the UK: breast, colon, lung and prostate.
Power calculations were performed assuming each re-
spondent would report raw cancer data on seven unique
individuals (grandparents, parents, siblings, and self ); an
average age of 55; equal gender distributions; and used
incidence rate standard deviations of 9.0/100,000 (the
maximum for the four cancers listed above) [27]. Such
calculations suggested that with 1,000 responses divided
between HHT and non-HHT respondents, the study
would have 80% power to detect a difference of 0.76/
100,000 in incidence rates for lung (or colon) cancer.
Since respondents and relatives would include men and
women, fewer individuals would be captured for detec-
tion of gender-specific cancers. However, the two fold
higher rates in the specific sex incidence rates for breast
and prostate cancer [27] rendered the calculations for
colorectal cancer broadly comparable.
Data for this study were downloaded on 30.6.2012,
when 1,307 individuals had responded. Although the sur-
vey remained open (for increasingly limited question sets
addressing outstanding medical questions) for a further
10 months, only 118 further individuals started the survey
in this period.
Patient population
Ascertainment of HHT status
All patients self reported their HHT status, but it was
critical to ensure that patients with HHT but unaware of
their final diagnosis were not assigned control status, and
conversely, that over-exuberant use of the HHT label was
not allowed to result in inappropriate assignment of HHT.
Therefore, questions were included to address the Cura-
çao criteria [32] which have been recently validated by a
major molecular study [33]. The criteria are nosebleeds,
mucocutaneous telangiectasia, visceral involvement (most
commonly gastrointestinal telangiectasia, or AVMs at spe-
cified sites), and family history. Details of the precise ques-
tion wording are provided in the Additional file 1. To
avoid bias, the telangiectasia question offered a variety of
potential sites for “red spots” in tick box options, only two
of which were to be considered as HHT telangiectasia
(see Additional file 1). A positive family history was de-
fined by a blood relative who had been diagnosed with
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any cancer-related questions, all HHT-diagnostic ques-
tions were reviewed independently by two members of the
HHT study team, to allow assignment of status as “HHT-
subject,” “control”, or “unknown” based on the Curaçao
criteria [32], and schematic in Figure 1. The senior author
reviewed all assignments. Participants assigned to the
“unknown” group were excluded from further data analysis.
In order to capture data on cancers with low incidence
and high mortality rates, information on family members
provided by the participants was used. Where the re-
spondent had HHT, the questions on which parent and
grandparent had HHT allowed deduction of which did
not, assuming autosomal dominant inheritance as present
in all reported HHT cases to date. Thus for HHT respon-
dents, where it was known which side of the family HHT
came from, HHT relatives could then be assigned asFigure 1 Stratification of diagnostic assignments. Flow chart indicating
stratified by whether they reported themselves as having HHT, and by the“HHT-subject,” “control”, or “unknown”. Specific care was
taken to avoid under-diagnosis of HHT that was not yet
manifest, thus controls were only selected from the side of
the family without HHT. The status of “HHT-patient” or
“control” (from HHT unaffected family branches) allo-
cated to family members was stringently assigned prior to
analyses of any cancer-related questions. A subgroup of
participants reported data during a period when software
data collection did not record the age of their parents. For
this subgroup, other age data (on themselves, their grand-
parents, their siblings and other deceased relatives) were
complete. For these respondents, parental ages were esti-
mated based on the mean age of mothers at first child-
birth using published data for the years 1970, 1980, 1990,
2000, 2003 and 2009 [34]. By cross referencing the names
of the oldest patient known in the family to have HHT,
and geographical location of the reported relatives, wethe application of the Curaçao Criteria to Survey Respondents,
presence or absence of a family history.
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multiple respondents. All status assignments were con-
cluded blinded to other demographic and cancer data.
Statistical methods
Basic demographic variables were calculated using STATA
IC versions 11 and 12 (Statacorp, Texas), and Graph Pad
Prism 5 (GraphPad Inc, US). An estimate of cancer rates
per 100,000 people per year was calculated by adjusting
for the specific population gender distribution and median
age at the diagnosis of cancer. Given the inherent limita-
tions of survey methodology, to assess if these estimates
may be realistic, calculations from cancer data reported
for controls in the current survey were compared to the
2008 age-standardised rates (ASRs) reported for the De-
veloped World by Globocan [27].
To address whether there may be a difference in rates
between the HHT patients and controls captured in com-
parable methods using the current methodology, two way
comparisons between HHT and control groups were per-
formed using Mann Whitney, examining only survey re-
spondents, only relatives, and combined data from all
respondents and relatives. Each specified cancer type was
used in turn as the dependent variable in logistic regres-
sion. Age-adjusted odds ratios for HHT status were calcu-
lated by performing logistic regression simultaneously
examining the effect of age and HHT status on each speci-
fied cancer: p values for contribution from HHT status
were calculated post estimation using the non parametric
Wald test which makes no assumption about independ-
ence of variables. To estimate age-standardised rates for
graphical presentations, each individual’s age was assigned
to all of the 1–10 decades of life they had achieved, and
cancers attributed to the decade in which they occurred.
Thus almost all individuals provided more than one dec-
ade of life for analyses. Age adjusted rates were calculated
for cancers where ages were specifically known, but inclu-
sion of cancers where uncertain ages were spread equally
across age groups did not materially alter the relationships.
Results
Survey population characteristics
At the time of data download, 1,307 participants had
completed the questionnaire. Evaluation of HHT diag-
nostic criteria, as detailed in Figure 1, resulted in assign-
ment of 1,007 with HHT, 158 unknowns (excluded from
further analyses in this study), and 142 controls.
As demonstrated in Table 1, there was no difference in
general demographics between HHT and control partici-
pants. Median ages were 55ys (range 18–90, interquartile
range (IQR) 46-64) and 53ys (range 21–86, IQR 42–61)
respectively; 65% of respondents were female (655/1012,
[64.7%] HHT; 92/142 [64.8%] control); and there was
also no difference in general demographics such as theinternational region of origin; diet as assessed crudely by
vegetarian status/red meat intake; alcohol intake; or expos-
ure to chemicals (Table 1). For smoking, similar percent-
ages were current or former smokers (315/1007 [31%]
HHT; 39/142 [27%] controls. Most were cigarette smokers,
and most had stopped smoking by the time of the survey
(Table 1). However, the smoking habit in terms of pack
years smoked per smoker was significantly higher for HHT
respondents than controls (Table 1). Crude cancer rates for
the two populations are presented in Additional file 2:
Table S1.Relatives and combined groupings
The survey also captured cancer data on 4,930 grandpar-
ents and parents. 1,154 were reported as HHT-affected.
2,675 relatives could be confidently assigned as controls
as they were either relatives of control respondents, or
from non-HHT branches of HHT families. The remaining
relatives (n = 1,101) could not be assigned as they were in
potentially HHT-affected branches of the families, and the
diagnosis of HHT may not yet have manifest [6-10], or
they had been potentially reported by other survey re-
spondents. Data from these relatives were therefore not
analysed.
The respective median ages of survey respondents were
53ys [IQR 42–61] for controls and 55ys [IQR 46–64] for
HHT subjects. Ages of reported relatives were higher at
median 77ys [IQR 67–82] for controls; median 72ys [IQR
62–82] for HHT-affected relatives. Combining data of par-
ticipants and relatives resulted in a control-arm of 2,817
(52% female, median age 77ys [IQR 65–82]), and HHT-
arm of 2,166, (58% female, median age 66ys [IQR 53–77]).Validation of survey methodology using control data
To validate the study methodology, the estimated
cancer rate (per 100,000 patients per year) was calcu-
lated for the control group, and compared to ASRs for
the Developed World from Globocan [27], recognising
that Globocan ASRs were for primary cancers at the
designated sites, whereas study methodology would
include reports of metastatic cancers. For the 18 most
common non-skin cancers, Table 2 presents the crude
data; adjustments for a population of average age 77ys,
52% female; and the ratios of the observed ASR/
expected ASR. These ratios ranged from 0.43 to 2.3
(median 1.23). For the 15 “predominantly primary”
cancers, the average ratio approximated to 1.0, compat-
ible with robust study methodology. We concluded that
while the data in the survey were not from a geograph-
ical or numerically-defined population, and while there
were inevitably concerns about self reported data,
nevertheless, the survey data for controls were reflective
of the cancer rates in the general population.
Table 1 Demographics for HHT and control survey respondents
Control HHT Total Mann Whitney
Total Count Mean SD Total Count Mean SD Total Count Mean SD p value
Gender (% female) 142 92 0.65 0.48 1007 654 0.65 0.48 1149 746 0.65 0.48 0.99
North America/Europe 142 124 0.87 0.33 1007 910 0.9 0.29 1149 1034 0.9 0.29 0.25
Australia/New Zealand 142 3 0.02 0.14 1007 42 0.04 0.2 1149 45 0.039 0.19 0.24
Asia 142 1 0.01 0.08 1007 4 0.004 0.06 1149 5 0.004 0.07 0.6
South America 142 0 0 0 1007 4 0.004 0.06 1149 4 0.004 0.06 0.45
Africa 142 0 0 0 1007 2 0.002 0.04 1149 2 0.0017 0.04 0.59
Current or former smoker 142 39 0.27 0.45 1007 315 0.31 0.46 1149 354 0.31 0.46 0.38
Current smoker 142 8 0.06 0.23 1007 67 0.07 0.25 1149 75 0.065 0.25 0.66
Former smoker 142 31 0.22 0.42 1007 248 0.25 0.43 1149 279 0.24 0.43 0.49
Passive smoker 142 1 0.01 0.08 1007 22 0.02 0.15 1149 22 0.019 0.14 0.24
Cigarettes 142 38 0.27 0.44 1007 308 0.31 0.46 1149 346 0.3 0.46 0.37
Number per week 38 38 0.31 0.23 308 308 0.34 0.33 346 346 38.1 21.4 0.4
Years smoked 38 38 15.8 13.5 308 308 17.3 11.5 346 346 17.1 13.4 0.37
Pack years per smoker 38 38 25.4 35.8 308 308 35.4 40 346 346 34 38.7 0.01
Cigars 142 3 0.02 0.14 1007 22 0.022 0.15 1149 25 0.022 0.15 0.96
Pipes 142 3 0.02 0.14 1007 18 0.018 0.13 1149 21 0.019 0.13 0.99
Other 142 1 0.01 0.84 1007 14 0.014 0.12 1149 15 0.013 0.11 0.5
Non vegetarian 130 123 0.95 0.23 969 929 0.96 0.2 1094 1047 0.96 0.21 0.51
Red meat 3x per week 130 75 0.58 0.5 950 542 0.57 0.5 1075 614 0.57 0.5 0.89
Industrial exposures 130 121 0.93 0.25 964 885 0.92 0.27 1090 1002 0.92 0.27 0.62
Alcohol 130 53 0.41 0.49 969 342 0.35 0.48 1099 395 0.36 0.48 0.22
Alcohol units per day 130 84 0.65 0.95 970 518 0.53 0.87 1095 602 0.55 0.88 0.17
Total: number of respondents reporting presences, absence or distribution of variable. Count: number of respondents with specified variable- demographics; originating in stated region; or describing stated intakes/
use/exposures. SD, standard deviation.
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Table 2 Calculation and comparison of age standardised rates (ASRs) for cancers in the control arm, compared to
reported general population data
Control survey population Globocan ASR ^ Ratio
Cases Cases per 100,000 ASR per 100,000^ ASR (men) ASR (women) ASR if 52% female Survey ASR/Globocan ASR
Bladder 9 319 4.1 16.3 3.6 9.7 0.43
Brain 21 745 9.7 5.8 4.4 5.1 1.91
Breast 91 3230 42.0 0.0 66.4 34.5 1.22
Cervical 14 497 6.5 0.0 9.1 4.7 1.36
Colorectal 56 1988 25.8 37.7 24.3 30.7 0.84
Kidney 11 390 5.1 11.9 5.9 8.8 0.58
Leukemia 17 603 7.8 9.1 5.9 7.4 1.05
Liver 27 958 12.4 8.2 2.7 5.3 2.33
Lung 106 3763 48.9 47.1 18.8 32.4 1.51
Lymphoma 19 674 8.8 12.5 9.0 10.7 0.82
Mouth 5 177 2.3 6.8 2.3 4.5 0.52
Myeloma 8 284 3.7 3.3 2.2 2.7 1.35
Oesophagus 9 319 4.1 6.5 1.3 3.8 1.09
Ovary 13 461 6.0 0.0 9.3 4.8 1.24
Pancreas 21 745 9.7 8.3 5.5 6.8 1.41
Prostate 56 1988 25.8 61.7 0.0 29.6 0.87
Stomach 39 1384 18.0 16.7 7.3 11.8 1.52
Uterus 20 710 9.2 0.0 13.0 6.8 1.36
General population ASRs were Globocan ASRs for “More Developed Regions”, 2008 [27]. The study data represent cancer cases in 2817 control participants or
relatives, with an average age of 77 ys, and 52% female. ^ Calculated assuming median age of 77 ys.
Figure 2 Validation data of cancer rates in controls. Comparison
of age-standardized rates (ASRs) for survey control arm and Globocan
ASRs for “More Developed Regions”, 2008. The study data represent
cancer cases in 2,817 control participants or relatives, with an average
age of 77 ys, and 52% female, and plots the observed/expected ratios
presented in Table 2, against the overall frequency of the specified
cancer, since variance would be expected to be greater for less
common cancers. Data are stratified by whether the cancers are
predominantly primary only (navy symbols, black solid line with 95%
confidence intervals); or primary and secondary sites (red symbols and
red dotted line).
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metastatic spread, namely lung, liver and brain. The ra-
tio of ASRs for these cancer types (range 1.5-2.3, median
1.9) was significantly higher than for the other 15 cancer
types (range 0.43-1.52, median 1.09, p = 0.013). Figure 2
illustrates the ASR ratios for the two subgroupings, plot-
ted against the frequency of the particular cancer type.
Since for the three “primary plus metastatic” sites, the
cancers were reported more commonly than expected
by primary ASRs, we concluded that the data were com-
patible with respondents reporting both primary and
metastatic cancers for lung, liver and brain.
Comparison of cancer rates in HHT patients and controls
Calculated cancer rates were then compared between the
survey HHT and control groups. In crude analyses, fewer
cancers were reported for HHT (398/2161, 18.4%) than
controls (668/2817, 23.7%, p = 0.0012). As noted in Figure 3
and Table 3, in these crude figures, there appeared to be a
lower frequency of solid tumours, and specifically of lung
cancers in the HHT arm compared to controls. Since pri-
mary and secondary lung and liver cancers carry high
mortality [28], and the HHT population comprised a
greater proportion of respondents (introducing a bias as
they needed to survive to the point of survey completion),
cancer rates were also examined in the “relatives only”
Figure 3 Reported numbers for haematological and solid cancers. Data are illustrated for the most common four cancers and
haematological cancers, in 2,166 HHT patients and 2,817 controls (Error bars indicate 95% confidence intervals).
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2,675 control relatives. This revealed higher rates of these
life-limiting cancers than in the younger survey respon-
dents, but again, the crude rates of lung and liver cancer
were lower in the HHTgroup than in controls: Crude liverTable 3 Crude incidence of the 20 most common non skin ca
Controls (n = 2817) †
Cancer cases Cases per 100,000 SEM
Bladder 9 320 106
Brain 21 746 162
Breast 91 3230 333
Cervical 14 497 133
Colorectal 56 1988 263
Kidney 11 391 118
Leukemia 17 604 146
Liver 27 959 184
Lung 106 3763 359
Lymphoma 19 675 154
Melanoma 67 2378 287
Mesothelioma 1 36 36
Mouth 5 178 79
Myeloma 8 284 100
Oesophagus 9 320 106
Ovary 13 462 128
Pancreas 21 746 162
Prostate 56 1988 263
Stomach 39 1384 220
Uterus 20 710 158
All cancers° 668 23713 800
† The control arm represented 142 survey respondents and 2,675 reported relatives
relatives. Note that for stomach and pancreatic cancer, the higher than expected co
appropriately assigned by respondents and relatives. ° All cancers includes less comcancer rates for the relatives-only groups (27 cases in con-
trols, 10 in HHT) were 1,009 and 866 per 100,000 respect-
ively. Crude lung cancer rates for the relatives-only groups
(101 cases in controls, 33 in HHT) were 3,775 and 2,860
per 100,000 respectively.ncers in both study arms
HHT (n =2161) ‡
Cancer cases Cases per 100,000 SEM p value
12 5090 153 0.3
11 463 146 0.21
80 3702 406 0.38
11 463 146 0.86
37 1712 279 0.47
11 463 146 0.7
7 324 122 0.16
11 463 146 0.042
38 1758 283 <0.0001
16 740 185 0.79
45 2082 307 0.48
0 0 0 0.38
7 324 122 0.3
4 185 93 0.48
4 185 93 0.35
13 602 166 0.5
9 417 139 0.14
33 1527 264 0.22
14 648 173 0.012
10 463 146 0.26
398 22351 834 0.0012
. ‡ The HHT arm represented 1,007 survey respondents and 1,154 reported
ntrol values (Table 2) suggest that these primary cancers may not have been
mon cancers. P value calculated by Mann Whitney.
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The individuals provided 36,887 separate decades of life
for analyses: 15,053 in the HHT arm and 21,834 decades
in the control arm. As expected, cancer rates were strongly
age-related (p < 0.0001, all cancers). Age adjusted incidence
rates were calculated for all cancers combined, and for the
most common cancers. These data indicated that after age-
adjustment, there was no significant difference in the over-
all rates of all cancers between HHTand controls (Table 4),
but this masked different patterns amongst the four most
common cancers: Following age-adjustment, there was no
difference in prostate or colorectal cancer rates, but breast
cancer was reported more frequently for HHT patients
(age-adjusted OR 1.52 (1.07, 2.14), p = 0.018), and lung
cancer significantly less frequently for HHT patients (age-
adjusted OR 0.48 [0.30, 0.77], p = 0.0023).
The study had not been powered to detect differences
in rates of liver cancer, but pooling with reported stom-
ach cancer was considered logical, given stomach cancer
was the most generic term available for abdominal can-
cer in these family reports, and was over-represented in
the control group compared to Globocan [28]. Pooled data
suggested HHT patients had fewer liver and stomach-
designated abdominal cancers than controls (age-adjusted
odd ratio 0.51 (0.25, 1.02), p = 0.059) (Table 5).Patterns of age-related changes
To examine whether there were trends for differences
between the HHT and control groups at specific periods
of their lives, quadratic regression was used to present
age-related changes graphically. As shown in Figure 4,
for prostate cancer, there was an exponential rise in can-
cer with age in both controls and HHT patients. The
best-fit quadratic regression line for HHT patients fitted
within the 95% confidence intervals for the best-fit line
in the control population. These graphs represent the
pattern that would be expected if there were no differ-
ences in prostate cancer rates in any age group, between
HHT patients and controls.Table 4 Crude and age adjusted HHT odds ratios for the
four most common cancers
Crude odds
ratio (95% CI)
p value Age adjusted odds
ratio (95% CI)
p value
All cancers 0.83 (0.72, 0.96) 0.012 1.04 ( 0.90, 1.21) 0.53
Prostate 1.11 (0.71, 1.76) 0.64 1.37 (0.87, 2.19) 0.18
Colorectal 1.04 (0.65, 1.65) 0.89 1.30 (0.81, 2.08) 0.28
Breast 1.18 (0.84, 1.65) 0.35 1.52 (1.07, 2.14) 0.018
Lung 0.38 (0.24, 0.60) <0.0001 0.48 (0.30, 0.77) 0.0023
Logistic regression was performed in all HHT patients and controls for all
cancers, colorectal and lung cancers, in males only for prostate cancer, and in
females only for breast cancer. The age adjusted p values for contribution of
HHT status were calculated post estimation using Wald test.For lung cancer, the control arm again demonstrated
an exponential rise with age (Figure 5). In contrast, the
best-fit line for lung cancer events in the HHT-arm was
more linear, and less steep than the comparable curve for
the controls. The 95% confidence intervals for the best-fit
curves diverged after the 5th decade of life. These graphs
represent the pattern that would be expected if lung can-
cer (primary or secondary) was less common in older
HHT patients compared to equivalently aged members of
the general population.
A similar trend was observed for liver cancer (Figure 6),
although the study had not been powered to detect a dif-
ference in this less common cancer type. With the wider
confidence limits, the 95% confidence intervals for the
best-fit curves did not quite diverge. Again, these graphs
represent the pattern that would be expected if liver can-
cer (primary or secondary) was less common in older
HHT patients compared to equivalently aged members of
the general population.
For breast cancer, a different pattern was observed.
For both controls and HHT patients there was a more
linear increase in breast cancer cases with age (Figure 7).
The curves diverged after 50 years of age but in this
case, it was the HHT population who showed a greater
increase of cancers with age. These graphs represent the
pattern that would be expected if breast cancer was more
common in older HHT patients compared to equivalently
aged members of the general population.
It had been expected that rates of colorectal cancer
would be higher in HHT because of the population sub-
group with SMAD4 mutations and juvenile polyposis.
Crude and age-adjusted analyses had not revealed an over-
all difference in colorectal cancer rates between the control
and HHT groups, but quadratic regression suggested a bi-
modal pattern (Figure 8). At younger ages, colorectal can-
cers were more common in HHT patients, but the rate of
rise with age was less steep than for controls, and at older
ages, the trend was for fewer cancers in HHT patients.
Discussion
In this study, using a new tool to capture rates of un-
common conditions within a rare disease population, we
demonstrated apparent differences in incidence of par-
ticular subtypes of cancer in HHT patients compared to
controls. Lung and liver/abdominal cancers appeared to
be less prevalent, and breast cancer more prevalent in
HHT patients. Overall, given the poorer survival from
lung and liver cancer compared to breast cancer, the data
could account for the surprisingly good life expectancy in
older HHT patients.
The strengths of this study included the use of new meth-
odology, designed as a family-based questionnaire powered
to detect differences in rates of the four most common
non-skin cancers between HHT patients and controls. The
Table 5 Crude and age adjusted HHT odds ratios for specified abdominal cancers
Crude odds ratio (95% CI) p value Age adjusted odds ratio (95% CI) p value
Liver 0.46 (0.18, 1.14) 0.095 0.59 (0.23, 1.49) 0.26
Stomach 0.43 (0.20, 0.95) 0.036 0.53 (0.24, 1.17) 0.12
Liver or stomach 0.51 (0.25, 1.03) 0.059 0.51 (0.25, 1.02) 0.059
Logistic regression was performed in all HHT patients and controls. The age adjusted p values for contribution of HHT status were calculated post estimation
using Wald test.
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cessibility of the questions, standardised and objective in-
clusion criteria applied after data capture, and acquisition
of data from a large number of subjects for a rare disease
population. Design of the survey prevented “hypothesis
guessing” by participants by using questions on other com-
mon health issues that concealed the purpose of each
section of the survey. Due to the familial nature of the con-
dition, participants exhibited willingness to report detailed
data on themselves and relatives, despite being unclear
exactly why the questions were being asked. The large con-
trol group permitted validation of methodologies by com-
paring ASRs for specific cancers in the captured controls, to
those reported for equivalent geographical populations.
Clearly there are limitations with this type of approach
which relies on retrospective recollections with potential
bias and honesty of data reporting. In addition, it may be
limited by uncertainty on precise details of the HHT diag-
nosis. This was addressed by not merely using self reported
status, but also using a rigorous algorithm that meant that
12% of completed datasets were not assignable either to
HHT or control status. While we cannot exclude that some
individuals reporting they had AVMs at particular sites, or
particular AVM treatments, were wrong, these were never
used in isolation for the diagnosis of HHT (Figure 1).
Absence of a molecular diagnosis in the majority of cases
may be considered a limitation by scientists, but as clini-
cians recognise, only a proportion of HHT families canFigure 4 Age-specific prostate cancer rates. Quadratic regression
plots for male-only HHT patients and controls. Shaded areas indicate
95% confidence intervals.receive a molecular diagnostic confirmation. Conversely,
given the currently debate regarding the disease-causing
status of many missense HHT mutations [35,36], in-
complete descriptions of a change in one of the HHT
genes were considerably more likely to be misreported
than a clinical phenotype that was familiar to the pa-
tient. The study was conducted on a predominantly
western, English-speaking population aged between 18
and 90 years of age, though cross references were made
to general population cancer data from equivalent coun-
tries. Detailed smoking and epidemiological habits of
relatives were not available, although with the exception
of smoking, the control and HHT respondent groups
were similar in virtually all demographics analysed. We
were particularly concerned with the potential bias of
survival to study participation, because lung and liver
cancers carry high mortality [28]. Had the reduced
number of lung and liver cancers observed in HHT
purely been due to survival bias (as participants needed
to survive to the point of survey completion), more
lung/liver cases should have been found in the HHT “rel-
atives only” subgroup. Since lower rates of lung and liver
cancer were reported for HHT relatives than control rela-
tives, we concluded that even allowing for potential sur-
vival bias, the data suggested a genuine reduction in these
cancers in HHT patients.
From laboratory and animal studies, there are oppos-
ing datasets suggesting HHT patients may be at higherFigure 5 Age-specific lung cancer rates. Quadratic regression plots
for all HHT patients and controls. Shaded areas indicate 95% confidence
intervals. Note primary and secondary lung cancers are not distinguished.
Figure 6 Age-specific liver cancer rates. Quadratic regression plots
for all HHT patients and controls. Shaded areas indicate 95% confidence
intervals. Note primary and secondary liver cancers are not distinguished.
Figure 8 Age-specific colorectal cancer rates. Quadratic regression
plots for all HHT patients and controls. Shaded areas indicate 95%
confidence intervals.
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complexity of multistep cancer pathogenesis, and the im-
portance of attempting to obtain data from patients, des-
pite the methodological limitations compared to laboratory
analyses. The majority of HHT patients have endoglin or
ALK1 mutations, and are haploinsufficient [35], expressing
approximately half normal endoglin or ALK1 in activated
monocytes, human umbilical vein endothelial cells, and
blood outgrowth endothelial cells [35-43]. Over-expression
of both endoglin and ALK-1 is seen during tumour de-
velopment and endothelial cell proliferation where new
vessels are formed to support tumour growth [44-53].
Consequences of acute changes in endoglin and ALK1
expression are yet to be fully determined but include
modulation of oncogenic genes such H-Ras; [45] DNA
repair enzymes [46], apoptosis [47], and resistance to
chemotherapy [46]. For metastases, while there are data
that acute use of anti-endoglin [47] or anti-ALK1Figure 7 Age-specific breast cancer rates. Quadratic regression
plots for female-only HHT patients and controls. Shaded areas indi-
cate 95% confidence intervals.antibodies [48] attenuate endothelial sprouting and other
early angiogenic processes, recent data suggest that long
term deficiency may render endoglin deficient mice at en-
hanced risk of tumour metastatic spread [49], and that
endoglin overexpression may be protective [50]. Con-
versely, there are data that cancer growth is reduced in
endoglin +/− mice [51,52]. Importantly, both endoglin and
ALK1 are emerging as successful targets for cancer ther-
apies in the general population: The use of a soluble
chimeric protein (ALK1-Fc), an inhibitor of ALK-1, has
been shown to result in significant tumour-suppression
both in vitro and in vivo [53]. Furthermore, Phase 1 and
Phase 2 human trials have been performed with anti-
endoglin antibodies with encouraging results [54,55].
Our hypothesis based on clinical observations and the
surprisingly good life expectancy data, was that cancer
rates would be lower in HHT patients: This interpretation
would be in-keeping with the data from the human trials
[53-55]. The current study was powered to detect differ-
ences in lung cancer rates, and these emerged as signifi-
cantly lower in HHT patients than controls ascertained
using the same methodology. We cannot rule out a chance
over-reporting of lung cancers only for the control arm, or
that HHT patients who would have gone on to develop
either primary lung cancer or lung metastases had already
died from HHT or other causes, although in the latter case,
as for lung cancer specific mortality above, we would have
expected to see a higher rate in the relatives arm, but did
not. The risk of primary lung cancer is strongly smoking
associated, but it is difficult to attribute the lower rates of
lung cancer to reduced smoking, as the data suggest
smoking rates were if anything, higher in HHT patients
compared to controls. Data from our ongoing 2013 HHT
Survey [56] provide a plausible reason: of the first 137
smokers, two (1.5%) stated smoking seemed to start a
nosebleed, but 13 (9.5%) stated smoking seemed to stop a
Figure 9 Age-specific rates of all solid, non-skin cancers. Quadratic
regression plots for all HHT patients and controls. Data include brain,
bladder, breast, cervical, colorectal, kidney, liver, lung, pancreas, prostate,
stomach uterus, mouth and oesophageal cancers. Shaded areas indicate
95% confidence intervals.
Figure 10 Age-specific rates of haematological cancers.
Quadratic regression plots for all HHT patients and controls. Data
include leukaemia, lymphomas and myeloma. Shaded areas indicate
95% confidence intervals.
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http://www.ojrd.com/content/8/1/195nosebleed (Mann Whitney p = 0.0062). We emphasise that
the hazards of smoking mean smoking should not be
viewed as a “therapeutic” option for HHT nosebleeds-
smoking cessation is strongly recommended for HHT
patients, as for the general population.
While the current study was underpowered to address
liver and other abdominal cancer rates, these too ap-
peared to be reduced. We therefore think it may be
relevant that comparisons to age-standardised rates in
the general population suggest a significant propor-
tion of reported lung, liver and brain cancers were
likely to be metastases from primary cancers else-
where (Table 2, Figure 2). For lung cancer, we suggest
it is possible that overall, HHT patients have natural
protection against tumour development in terms of
tumour initiation, growth, and/or metastases. Irre-
spective of the mechanism (s), given the dismal sur-
vival rates once lung cancer is present [28], reduced
rates of lung cancer could account for the life expect-
ancy paradox evident in the HHT population.
In view of case reports and evidence that colorectal can-
cer risks are higher for patients with SMAD4 mutations,
we were surprised that the risk of colorectal cancer did
not emerge more strongly for participants and/or relatives
with HHT. The age-related changes would support an
interpretation allowing for an enhanced risk in early life
(most likely consequent on SMAD4 and polyposis predis-
positions), but possible protection from other forms of
colorectal cancer later in life.
Breast cancer was also expected to be higher in
HHT patients: As for any discipline in which screen-
ing and treatment modalities include exposure to ion-
ising radiation, there are discussions about the degree
to which health benefits may be offset by an increase
in cancer rates [57-61]. In HHT, this is particularly
true for brain, lung and breast tissues which lie
within the radiation exposure fields for CT scans and
angiographic studies that are essential to treat HHT
cerebral and pulmonary AVMs respectively. Furthermore,
endoglin, the protein mutated in HHT type 1, has been
shown to suppress invasion and metastasis of breast can-
cer, with lower endoglin expression in the tumour com-
partment correlating with poorer clinical outcome [54].
Since HHT patients with endoglin mutations express ap-
proximately half normal endoglin [37-43], there would
therefore be even more reason to predict that breast can-
cer rates should be higher in HHT patients. However, only
a modest increase was observed (age-adjusted OR 1.52
(1.07, 2.14), p = 0.018). Whether this increase would be
lessened by reduced radiation exposure is testable, but it is
important to recognise that the lifetime risks of breast
cancer (<1%) are substantially lower than the risks of
strokes, brain abscess, and other complications, which are
prevented by PAVM embolisation.Due to the divergent patterns particularly for lung and
breast cancer, there were no evident trends comparing all
solid cancers (Figure 9). This provides a cautionary note re-
garding pooling different disease states when faced with
the demanding logistical or statistical requirements for
studying comorbidities in patients with rare diseases. This
could have been done in this study, for example powering
the study to detect a difference in “all cancers”, “all solid
cancers”, or “all haematological cancers”. There were also
no differences in the rates of pooled haematological
cancers between HHT patients and controls (Figure 10).
Instead of speculating on potential reasons, we prefer to
emphasise that the study was underpowered to detect dif-
ferences even when pooled, and that, as for solid cancers,
pooling may have masked important differences between
individual cancer types.
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Overall, for rare diseases in which longitudinal studies
would take decades to recruit equivalent datasets pro-
spectively, we suggest that this type of methodology is a
good first-step method for data collection. Rapid high pro-
file advertising in the specific populations (particularly via
well established patient support groups with links through
email, facebook and twitter to hundreds or thousands of af-
fected/interested potential participants) renders prolonged
data capture periods unnecessary. Such a tool provides the
opportunity to address comorbidity risk reductions in rare
disease populations, instead of risk increases which are eas-
ier to address statistically. Providing patients with rapid
feedback from their participation in a somewhat arduous
questionnaire is likely to increase their willingness to par-
ticipate in further studies. This is important for rare disease
populations where future research studies are likely to tar-
get the same patient groups. Additionally, if multiple re-
search questions are addressed in the same survey, this
reduces reporter bias, offers opportunities for almost im-
mediate delivery of results that matter to patients [7,22,30],
yet could potentially be used to capture data of more inter-
est to researchers than the participants themselves.
For the HHT community, these study results are reassur-
ing on multiple levels, and particularly in terms of absolute
lung, breast, brain and colorectal cancer rates given the in-
evitable speculation regarding potential risks based on
available laboratory evidence. We suggest that the findings
are also important to the scientific community, as they
suggest that HHT patients may be protected from common
cancers. Further studies are recommended to assess if
factors that may be protecting the HHT population could
also be harnessed for the benefit of the general population.
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